Economic implications of treatment guidelines for congestive heart failure

Canadian Journal of Cardiology

Volumn 21, Issue 14, 2005, Pages 1301-1306

  Shibata, Marcelo C ^a   Nilsson, Carolyn ^a   Hervas Malo, Marilou ^a   Jacobs, Philip ^a   Tsuyuki, Ross T ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Congestive heart failure; Economic analysis; Hospitalizations; Treatment guidelines

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SPIRONOLACTONE;

ADULT; ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; DRUG EFFICACY; DRUG USE; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE QUALITY; HEALTH ECONOMICS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; PRACTICE GUIDELINE;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CANADA; DATABASES; DIGOXIN; DRUG COSTS; DRUG UTILIZATION REVIEW; GUIDELINE ADHERENCE; HEART FAILURE, CONGESTIVE; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; PRACTICE GUIDELINES; SPIRONOLACTONE;

EID: 31744437905     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas: American Heart Association, 2001.
2. Heart and Stroke Foundation of Canada. The Changing Face of Heart Disease and Stroke in Canada. Ottawa: Heart and Stroke Foundation of Canada, 1999.
3. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88:107-15.
4. Cowie MR, Wood DA, Coats AJ, et al. Survival of patients with a new diagnosis of heart failure: A population based study. Heart 2000;83:505-10.
5. Brophy JM. Epidemiology of congestive heart failure: Canadian data from 1970 to 1989. Can J Cardiol 1992;8:495-8.
6. Tsuyuki RT, Shibata MC, Nilsson C, Hervas-Malo M. Contemporary burden of illness of congestive heart failure in Canada. Can J Cardiol 2003;19:436-8.
7. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450-6. (Erratum in 1995;274:462).
8. Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail 2001;3:351-7.
9. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
10. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
11. Bungard TJ, McAlister FA, Johnson JA, Tsuyuki RT. Underutilisation of ACE inhibitors in patients with congestive heart failure. Drugs 2001;61:2021-33.
12. Liu F, Arnold M, Belenkie I, et al; Canadian Cardiovascular Society. The 2001 Canadian Cardiovascular Society consensus guideline update for the management and prevention of heart failure. Can J Cardiol 2001;17(Suppl E):5E-24E.
13. World Health Organization International Classification of Diseases (ICD). (Version current at November 21, 2005).
14. Tsuyuki RT, Fradette M, Bungard TJ, et al. Improving the use of ACE inhibitors in patients with congestive heart failure: The review of education on ACE inhibitors in congestive heart failure treatment (REACT) study, stage 1. Can J Cardiol 2001;17(Suppl C):105C.
15. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
16. A National List of Provincial Costs for Health Care: Canada 1997/8. (Version current at November 21, 2005).
17. Alberta Health and Wellness Drug Benefit List. (Version current at November 21, 2005).
18. Standing Medical Advisory Committee. The use of statins. London: Department of Health, 1997 (11061 HCD Aug 97[04]).
19. Freemantle, N, Barbour R, Johnson R, Marchment M, Kennedy A. The use of statins: A case of misleading priorities? BMJ 1997;315:826-8.
20. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190-5.
21. Tsuyuki RT, McKelvie RS, Arnold JM, et al. Acute precipitants of congestive heart failure exacerbations. Arch Intern Med 2001;161:2337-42.
22. McAlister FA, Lawson FM, Teo KK, Armstrong PW. A systematic review of randomized trials of disease management programs in heart failure. Am J Med 2001;110:378-84.
23. Statistics Canada. (Version current at November 21, 2005).
24. Schedule of Medical Benefits, Alberta Health and Wellness. (Version current at November 21, 2005).